Renovaro Inc. (NASDAQ:RENB - Get Free Report) saw a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 3,870,000 shares, a growth of 27.7% from the November 30th total of 3,030,000 shares. Currently, 5.0% of the company's shares are short sold. Based on an average daily trading volume, of 869,400 shares, the short-interest ratio is presently 4.5 days.
Hedge Funds Weigh In On Renovaro
Several hedge funds have recently bought and sold shares of RENB. Barclays PLC lifted its position in shares of Renovaro by 315.7% during the third quarter. Barclays PLC now owns 69,531 shares of the company's stock worth $34,000 after purchasing an additional 52,804 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Renovaro by 347.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 93,010 shares of the company's stock valued at $45,000 after buying an additional 72,230 shares in the last quarter. Rhumbline Advisers bought a new stake in Renovaro during the 2nd quarter valued at about $79,000. Bank of New York Mellon Corp purchased a new stake in Renovaro in the 2nd quarter valued at about $220,000. Finally, State Street Corp grew its stake in Renovaro by 3.8% in the 3rd quarter. State Street Corp now owns 1,323,832 shares of the company's stock worth $640,000 after acquiring an additional 48,114 shares in the last quarter. Institutional investors own 71.41% of the company's stock.
Renovaro Price Performance
Shares of RENB traded down $0.04 during midday trading on Tuesday, hitting $0.84. The stock had a trading volume of 366,774 shares, compared to its average volume of 628,313. The stock's 50 day moving average is $0.91 and its 200 day moving average is $0.90. The firm has a market cap of $132.61 million, a PE ratio of -0.87 and a beta of 0.65. Renovaro has a 1 year low of $0.40 and a 1 year high of $5.25.
Renovaro (NASDAQ:RENB - Get Free Report) last posted its quarterly earnings data on Thursday, October 10th. The company reported ($0.45) earnings per share for the quarter.
About Renovaro
(
Get Free Report)
Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.
Recommended Stories
Before you consider Renovaro, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Renovaro wasn't on the list.
While Renovaro currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
